Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Kaduri

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Genetic Counseling|July 5, 2015
The Effect of Genetic Counseling on Knowledge and Perceptions Regarding Risks for Breast CancerM Sagi, L Kaduri, J Zlotogora, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Determinants of the use of complementary therapies by patients with cancerO Paltiel, M Avitzour, T Peretz, et al.
American Journal of Human Genetics|March 1, 1997
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi womenD Abeliovich, L Kaduri, I Lerer, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 31, 1999
Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiersL Kaduri, M Gibs, A Hubert, et al.
British Journal of Cancer|February 19, 2004
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanomaM Lotem, E Shiloni, I Pappo, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Genetic Counseling|July 5, 2015
The Effect of Genetic Counseling on Knowledge and Perceptions Regarding Risks for Breast CancerM Sagi, L Kaduri, J Zlotogora, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Determinants of the use of complementary therapies by patients with cancerO Paltiel, M Avitzour, T Peretz, et al.
American Journal of Human Genetics|March 1, 1997
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi womenD Abeliovich, L Kaduri, I Lerer, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|July 31, 1999
Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiersL Kaduri, M Gibs, A Hubert, et al.
British Journal of Cancer|February 19, 2004
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanomaM Lotem, E Shiloni, I Pappo, et al.
Pageof 1